This paper compares PV with the more commonly used ESR and C-reactive protein (CRP) in rheumatoid arthritis (RA) firstly as a diagnostic aid and secondly as an index of improvement during specific antirheumatic drug therapy. The specific effect of individual drugs used in the treatment of rheumatoid arthritis on PV, ESR, and CRP is also investigated.
In 1976 the Lancet' reported 'the ESR has successfully resisted other challengers in the past, though after 50 years pathologists would not be sorry to see it go.' This comment prompted us to look at the alternatives, in particular plasma viscosity (PV). The measurement of PV to detect nonspecific changes in one or more plasma protein fractions has been reviewed by Harkness.2 It was first advocated as an index of activity in the rheumatic diseases by Whittington.3 Subsequent evidence of its superiority over the erythrocyte sedimentation rate (ESR) has been described,4 but to date this view has not been rigorously quantified.
This paper compares PV with the more commonly used ESR and C-reactive protein (CRP) in rheumatoid arthritis (RA) firstly as a diagnostic aid and secondly as an index of improvement during specific antirheumatic drug therapy. The specific effect of individual drugs used in the treatment of rheumatoid arthritis on PV, ESR, and CRP is also investigated.
Patients and methods
The use of PV as a diagnostic aid was investigated in a selection of 120 patients with classical or definite RA (American Rheumatism Association criteria). None had received specific antirheumatic therapy (e.g., gold, penicillamine, hydroxychloroquine) and all showed evidence of at least moderate disease (Table 1) . Table 2 ). The failure of alclofenac to improve disease status9 is exemplified by the lack of improvement in biochemistry and articular index over the 24-week period ( Fig. 1 and Table 2 ). At the end of the 6-month period it was observed that, of the 60 patients treated. 8 had normal ESRs but still had raised PV and CRP. Only 1 patient showed evidence of a raised ESR but normal PV.
The correlation of PV, CRP, and ESR with disease activity at a given time is illustrated in Tables 3 and 4 . Alclofenac data omitted-insufficient data due to patient withdrawal. Al = articular index. In terms of correlation with articular index alone ( improvement (measured as improvement in articular index) than did ESR. Correlations with articular index were significant for all parameters measured with the exception of the alclofenac-treated group, where correlations were poor owing to patient withdrawal, lack of response, and consequent 'baseline variability' in all parameters.
Discussion
In comparison with the ESR the PV has been shown previously to have a number of distinct advantages.2
For example, its range for normal subjects is independent of age and sex and is well defined, its sensitivity is greater, becoming abnormal earlier in the disease (a small change only in the order of 003-005 centipoise has clinical significance) and the incidence of false positives and negatives is lower. In addition, reproducibility studies have indicated a very small experimental error of about O05%,2 a figure confirmed in our own studies. Each test takes only 1 minute to perform, and interlaboratory variation is negligible. Blood specimens can be tested up to 1 week after collection in contrast to a 4-hour limit on ESR (24 hour limit for EDTA plasma).
Harkness2 has also argued that PV can be used to detect 'quiescent' activity, that is, even in the absence of clinical symptoms and with a normal ESR a high PV may indicate persistent abnormalities in plasma proteins and the possibility of relapse on drug withdrawal. Our week 24 data, showing a greater incidence of patients with normal ESR and raised PV rather than vice versa, would argue in favour of this hypothesis.
The ESR has also been compared unfavourably with CRP levels,"l serum CRP correlating more closely than ESR with radiographic lesions in RA.12
In terms of correlation with clinical status the present results show minimal differences overall between ESR, CRP, and PV (Tables 3, 4 , and 5). While a slight preference could be argued for ESR or CRP for D-penicillamine-treated patients,5 the use of ESR is perhaps questionable only during hydroxychloroquine therapy owing to the lack of significant change observed ( Fig. 1 and Table 2 ). The failure of ESR to return towards normal despite clinical improvement has also been reported for 34 RA patients treated for 16 weeks with chloroquine. 13 It is possible that chloroquine and hydroxychloroquine may have a specific action on erythrocytes which affects rouleaux formation and hence the ESR.
Our data indicate that PV estimations are at least as reliable as ESR and CRP in terms of diagnosis and as indices of disease activity and improvement during specific antirheumatoid drug therapy. However, in terms of both methodology and the detection of 'quiescent" disease activity PV estimations may have distinct advantages over other more traditional indices. 
